Krose 20 Gold Capsule is a combination medication containing Aspirin (75 mg), Rosuvastatin (20 mg), and Clopidogrel (75 mg), primarily indicated for the prevention of cardiovascular events in patients at high risk of atherosclerotic disease. Aspirin acts as an antiplatelet agent by irreversibly inhibiting cyclooxygenase, thereby reducing thromboxane A2 production and platelet aggregation. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers LDL cholesterol and triglycerides while modestly increasing HDL cholesterol, contributing to plaque stabilization and reduced progression of atherosclerosis. Clopidogrel, another antiplatelet agent, inhibits the P2Y12 component of ADP receptors on platelet surfaces, preventing platelet activation and aggregation. The combined action of these agents provides comprehensive cardiovascular protection by reducing the risk of myocardial infarction, stroke, and other thrombotic complications in patients with established cardiovascular disease or multiple risk factors. Krose 20 Gold Capsule should be used under medical supervision, considering potential contraindications such as active bleeding, hypersensitivity, or severe hepatic impairment. Regular monitoring of lipid profiles, liver function, and bleeding parameters is recommended during therapy. Adverse effects may include gastrointestinal discomfort, bleeding tendencies, and rare hypersensitivity reactions. Patient adherence and lifestyle modifications are essential to maximize therapeutic outcomes.